Why the study?
In-stent restenosis remains a major issue after PCI, and its clinical burden is expected to grow with rising risk factors and complex interventions.
Key points are not available for this paper at this time.
Design
Review
Answers are grounded in this paper and cite their sources.
ISR persists as a major PCI driver; leaves open optimal prevention and management strategies.
Despite ongoing progress in stent technology and deployment techniques, in-stent restenosis (ISR) still remains a major issue following percutaneous coronary intervention (PCI) and accounts for 10.6% of all interventions in the United States. With the continuous rise in ISR risk factors such as obesity and diabetes, along with an increase in the treatment of complex lesions with high-risk percutaneous coronary intervention (CHIP), a substantial growth in ISR burden is expected. This review aims to provide insight into the mechanisms, classification, and management of ISR, with a focus on exploring innovative approaches to tackle this complication comprehensively, along with a special section addressing the approach to complex calcified lesions.
No takes yet. Share an insight, caveat, or question.
Hassani et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: